INTRODUCTION
============

Anaphylaxis is now universally defined as a serious allergic reaction that is rapid in onset and can cause death \[[@B1]\]. It is a medical emergency affecting more people in different parts of the world, with overall mortality risk estimated at 1%. In the 2015 updates on epidemiology of anaphylaxis, the Word Allergy Organization (WAO) reported that hospitalizations due to anaphylaxis have been increasing \[[@B1][@B2][@B3]\].

Several studies have attempted to establish the true incidence of anaphylaxis in the Emergency Department (ED). Previously, the absence of a universal definition of anaphylaxis leading to variations in the interpretation and then underreporting and miscoding, made research on this disease difficult and inaccurate. In July 2005, the National Institute of Allergy and Infectious Disease and the Food Allergy and Anaphylaxis Network (NIAID/FAAN) created a universally accepted definition and criteria for diagnosis and guidelines on the management of anaphylaxis \[[@B1]\]. These clinical criteria for the diagnosis of anaphylaxis have been validated in ED studies in children, teenagers, and adults as having high sensitivity (96.7%), reasonable specificity (82.4%), and a high negative predictive value (98%) \[[@B1][@B4][@B5]\].

In the ED, diagnosis and management of anaphylaxis remains challenging because symptoms are nonspecific, may resemble other conditions, and appears and progresses rapidly after exposure to a trigger \[[@B1]\]. There has been no known laboratory test which can confirm or rule out diagnosis of anaphylaxis, which could then promptly aid in the decision making on treatment upon arrival of a patient at the ED. The diagnosis of anaphylaxis thus largely relies upon the history and physical examination of the attending health professional \[[@B6]\]. It has been estimated that at least 50% of anaphylaxis episodes are misdiagnosed in the ED when the diagnostic criteria of current guidelines are not used \[[@B7]\].

The objective of the present study was to determine the incidence of anaphylaxis in the ED of a tertiary care hospital in the Philippines as identified by the NIAID/FAAN Criteria, and describe characteristics of these anaphylaxis cases, their management and outcomes.

MATERIALS AND METHODS
=====================

Study design
------------

This study was a retrospective descriptive research, using chart review to identify and describe cases of anaphylaxis seen at the ED of The Medical City Hospital, a tertiary hospital in a major city in the Philippines.

Purposive sampling and complete enumeration of all cases of anaphylaxis identified through the hospital electronic records was done. All records of patients seen at ED from January, 2013 to December, 2015 with specific International Statistical Classification of Diseases, 10th revision (ICD-10) codes including (1) anaphylactic shock due to adverse food reaction T78.0, (2) anaphylactic shock, unspecified T78.2, (3) angioneurotic edema T78.3, (4) allergic reaction, not otherwise specified, hypersensitivity not otherwise specified T78.4, (5) anaphylactic shock due to adverse effect of correct drug or medicament properly administered T78.6, (6) allergic urticaria L50.0, (7) idiopathic urticaria L50.1, (8) urticaria unspecified L50.9, and (9) generalized skin eruption due to drug and medicaments L27.0, were reviewed.

The study was approved by the Institutional Review Board of The Medical City Hospital (approval number: GCS Ped 2016-013).

Study population
----------------

The 2 authors reviewed together all the charts identified. Study population included all pediatric (age \< 18 years) and adult (age ≥ 18 years) cases of anaphylaxis seen at the ED from January 2013 to December 2015, who satisfied the 2005 NIAID/FAAN clinical criteria for the diagnosis of anaphylaxis, regardless of the initial diagnosis assigned to them in the ED report. The 2005 NIAID/FAAN clinical criteria were used as this was the criteria included in the ED manual of the hospital at the time the study was done. These identified cases of anaphylaxis were divided into 2 groups: (1) diagnosed as anaphylaxis or (2) not diagnosed as anaphylaxis/other allergy-related diagnosis at ED.

We recorded demographic data, clinical symptoms, treatment received, triggers suspected by the patient and the ED physician, outcome of the anaphylactic episode, and the final diagnosis.

Patients who did not satisfy the NIAID/FAAN criteria for diagnosing anaphylaxis were excluded from the study.

The number of patients admitted daily to the ED was also recorded.

Statistical analysis
--------------------

Descriptive statistics used in this study were the following: frequency, percentage, mean and range. Chi-square was used to determine whether epinephrine administration and time interval of administration from time of arrival at ED were dependent on the diagnosis, and whether diagnosis was dependent on specific clinical features.

RESULTS
=======

Incidence of anaphylaxis
------------------------

Out of the 344,823 pediatric and adult patients seen at the ED from January 2013 to December 2015, a total of 105 cases of anaphylaxis were identified using the NIAID/FAAN criteria. There was only one readmitted patient due to anaphylaxis; the second episode occurring 1 year after. Thus, the study gathered 105 cases of anaphylaxis in 104 patients. Incidence rate for the 3-year study period was 0.03% or 0.34 episodes per 1,000 ED visit.

Out of 105 cases, 66.7% were diagnosed as anaphylaxis, while 33.3% were diagnosed as other allergy-related disease: "hypersensitivity reaction" (18.1%) or "urticaria" (15.2%). All patients diagnosed as anaphylaxis fit the criteria of NIAID/FAAN.

Characteristic of the study population
--------------------------------------

Among anaphylaxis cases, 55.2% were females. There was an almost equal distribution of cases between pediatric (49.6%) and adult (50.4%) age groups. Among anaphylaxis cases, 11.4% had at least one previous episode of anaphylaxis. Majority (77.1%) had history of atopy, while 50.5% had family history of atopy ([Table 1](#T1){ref-type="table"}).

###### Patient characteristics (n = 105)

![](apa-10-e1-i001)

  Characteristic                No. of cases (%)                    
  ----------------------------- ----------------------------------- -----------
  Sex                                                               
                                Male                                47 (44.8)
                                Female                              58 (55.2)
  Age (yr)                                                          
                                0--5                                7 (6.7)
                                6--9                                9 (8.6)
                                10--18                              36 (34.3)
                                19--29                              18 (17.1)
                                30--39                              15 (14.3)
                                40--59                              14 (13.3)
                                ≥60                                 6 (5.7)
  With history of anaphylaxis   12 (11.4)                           
  History of atopic disease     81 (77.1)                           
                                Asthma                              32 (30.5)
                                Food allergy                        44 (41.9)
                                Drug allergy                        24 (22.9)
                                Allergy aside from food and drugs   7 (6.7)
                                Allergic rhinitis                   8 (7.6)
                                Atopic dermatitis                   3 (2.9)
  Family history of atopy       53 (50.5)                           
  Intake of medications                                             
                                ACE inhibitors                      5 (4.8)
                                Beta blockers                       4 (3.8)
                                NSAID                               1 (0.9)
  Medical comorbidity           17 (16.2)                           
                                Hypertension                        14 (13.3)
                                Other cardiovascular disease        2 (1.9)

ACE, angiotensin-converting-enzyme; NSAID, nonsteroidal anti-inflammatory drug.

A previous history of anaphylaxis had no effect on whether the patients were eventually diagnosed with anaphylaxis or not ([Table 2](#T2){ref-type="table"}).

###### Diagnosis of anaphylaxis in relation to history of anaphylaxis

![](apa-10-e1-i002)

  History of anaphylaxis   Anaphylaxis cases   Total       
  ------------------------ ------------------- ----------- -----------
  No                       62 (66.7)           31 (33.3)   93 (88.6)
  Yes                      8 (66.7)            4 (33.3)    12 (11.4)
  Total                    70 (66.7)           35 (33.3)   105 (100)

Values are presented as number (%).

ED, Emergency Department.

χ^2^ = 0.0, *p* \> 0.05.

In both age groups, majority had no identifiable obvious cause (38.1%) ([Table 3](#T3){ref-type="table"}). In those that had an identifiable trigger based on history alone, the most common were food (34.3%) and drugs (20%). The diagnosis of anaphylaxis was independent of the triggers identified

###### Identified triggers of anaphylaxis

![](apa-10-e1-i003)

  Trigger of anaphylaxis   Child (n = 52)                                Adult (n = 53)   Total (n = 105)   
  ------------------------ --------------------------------------------- ---------------- ----------------- -----------
  Food                     19 (18)                                       17 (16.1)        36 (34.3)         
                           Crustacean                                    7 (6.6)          9 (8.6)           16 (15.2)
                           Fish                                          3 (2.8)          3 (2.8)           6 (5.7)
                           Peanut                                        5 (4.8)          0 (0)             5 (4.8)
                           Chicken                                       1 (1)            3 (2.8)           4 (3.8)
                           Sesame seed                                   0 (0)            1 (1)             1 (1)
                           Raisin                                        0 (0)            1 (1)             1 (1)
                           Fried rice                                    1 (1)            0 (0)             1 (1)
                           Chocolate                                     1 (1)            0 (0)             1 (1)
                           Noodles                                       1 (1)            0 (0)             1 (1)
  Drugs                    10 (9.5)                                      11 (10.5)        21 (20)           
                           NSAID                                         5 (4.8)          6 (5.7)           11 (10.4)
                           Paracetamol                                   1 (1)            1 (1)             2 (1.9)
                           Amoxicillin                                   1 (1)            1 (1)             2 (1.9)
                           Coamoxiclav (amoxicillin + clavulanic acid)   2 (1.9)          1 (1)             3 (2.8)
                           Cefalexin                                     0 (0)            1 (1)             1 (1)
                           Probiotics                                    1 (1)            0 (0)             1 (1)
                           Hyoscine                                      0 (0)            1 (1)             1 (1)
                           Radiocontrast media                           1 (1)            1 (1)             2 (1.9)
                           Rabies vaccine                                0 (0)            1 (1)             1 (1)
  Insect bite/sting        1 (1)                                         4 (3.8)          5 (4.8)           
  Unknown                  21 (2)                                        19 (18.1)        40 (38.1)         

Values are presented as number (%).

NSAID, nonsteroidal anti-inflammatory drug.

χ^2^ = 3.788, *p* \> 0.05.

The most frequently involved organs were that of the skin and lungs. Difficulty of breathing was the most common chief complaint (48.6%) and overall symptom (90.5%). Pruritus was the most common skin symptom (85.7%) ([Table 4](#T4){ref-type="table"}). The diagnosis of anaphylaxis was shown to be dependent on the presence of specific symptoms such as wheezing, low oxygen saturation, hypotension, and abdominal pain ([Table 5](#T5){ref-type="table"}).

###### Chief complaint and signs and symptoms of anaphylaxis cases
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  Variable             No. of cases (n = 105)                                
  -------------------- --------------------------- ------------------------- -----------
  Chief complaints                                                           
                       Difficulty of breathing     51 (48.6)                 
                       Rashes                      31 (29.5)                 
                       Eye swelling                11 (10.5)                 
                       Chest pain/tightness        3 (2.9)                   
                       Throat discomfort           2 (1.9)                   
                       Generalized body weakness   3 (2.9)                   
                       Loss of consciousness       1 (1)                     
                       Abdominal pain              1 (1)                     
                       Nausea                      1 (1)                     
                       Dizziness                   1 (1)                     
  Signs and symptoms                                                         
                       Respiratory                                           
                                                   Difficulty of breathing   95 (90.5)
                                                   Wheezing                  68 (64.8)
                                                   O~2~ saturation \< 95%    22 (21)
                                                   Cough                     14 (13.3)
                                                   Rhinorrhea                11 (10.5)
                                                   Choking                   4 (3.8)
                                                   Stridor                   1 (1)
                       Skin                                                  
                                                   Pruritus                  90 (85.7)
                                                   Urticaria                 61 (58.1)
                                                   Flushing                  43 (41)
                                                   Periorbital edema         37 (35.2)
                                                   Erythema                  12 (11.4)
                                                   Conjunctival redness      9 (8.6)
                                                   Lip swelling              8 (7.6)
                                                   Tearing                   7 (6.7)
                       Cardiovascular                                        
                                                   Tachycardia               55 (52.4)
                                                   Hypotension               17 (16.2)
                                                   Chest pain                17 (16.2)
                                                   Syncope                   6 (5.7)
                                                   Arrhythmia                3 (2.9)
                                                   Palpitation               4 (3.8)
                       Gastrointestinal                                      
                                                   Abdominal pain            17 (16.2)
                                                   Vomiting                  15 (14.3)
                                                   Diarrhea                  4 (3.8)
                                                   Nausea                    2 (1.9)
                       Central nervous system                                
                                                   Dizziness                 7 (6.7)
                                                   Weakness                  5 (4.8)
                                                   Headache                  1 (1)

Values are presented as number (%).

###### Diagnosis of anaphylaxis in relation to presence of symptoms
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  Symptom                   Anaphylaxis cases   χ^2^ (*p* value)               
  ------------------------- ------------------- ------------------ ----------- ---------------------
  Difficulty of breathing                                                      1.382 (\>0.05)
                            Absent              5 (50)             5 (50)      10 (9.5)
                            Present             65 (68.4)          30 (31.6)   95 (90.5)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Wheezing                                                                     4.090 (\<0.05^\*^)
                            Absent              20 (54.1)          17 (45.9)   37 (35.2)
                            Present             50 (73.5)          18 (26.5)   68 (64.8)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  O~2~ saturation \< 95%                                                       4.859 (\<0.05^\*^)
                            Absent              51 (61.4)          32 (38.6)   83 (79)
                            Present             19 (86.4)          3 (13.6)    22 (21)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Urticaria                                                                    2.367 (\>0.05)
                            Absent              33 (75)            11 (25)     44 (41.9)
                            Present             37 (60.7)          24 (39.3)   61 (58.1)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Flushing                                                                     0.020 (\>0.05)
                            Absent              41 (66.1)          21 (33.9)   62 (59)
                            Present             29 (67.4)          14 (32.6)   43 (41)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Periorbital edema                                                            1.022 (\>0.05)
                            Absent              43 (63.2)          25 (36.8)   68 (64.8)
                            Present             27 (73)            10 (27)     37 (35.2)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Tachycardia                                                                  0.019 (\>0.05)
                            Absent              33 (66)            17 (34)     50 (47.6)
                            Present             37 (67.3)          18 (32.7)   55 (52.4)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Hypotension                                                                  4.246 (\<0.05^\*^)
                            Absent              55 (62.5)          33 (37.5)   88 (83.8)
                            Present             15 (88.2)          2 (11.8)    17 (16.2)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Chest pain                                                                   0.561 (\>0.05)
                            Absent              60 (68.2)          28 (31.8)   88 (83.8)
                            Present             10 (58.8)          7 (41.2)    17 (16.2)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Abdominal pain                                                               12.669 (\<0.01^\*^)
                            Absent              65 (73.9)          23 (26.1)   88 (83.8)
                            Present             5 (29.4)           12 (70.6)   17 (16.2)
                            Total               70 (66.7)          35 (33.3)   105 (100)
  Vomiting                                                                     0.350 (\>0.05)
                            Absent              59 (65.6)          31 (34.4)   90 (85.7)
                            Present             11 (73.3)          4 (26.7)    15 (14.3)
                            Total               70 (66.7)          35 (33.3)   105 (100)

Values are presented as number (%).

ED, Emergency Department.

Management of anaphylaxis
-------------------------

[Fig. 1](#F1){ref-type="fig"} shows epinephrine administration between the cases diagnosed versus those not diagnosed as anaphylaxis. Seventy-three cases (69.5%) received epinephrine. Significantly more patients were given epinephrine when given the diagnosis of anaphylaxis as compared to those who were not (61,87.1% vs. 12, 34.3%, χ^2^ = 30.767, *p* \< 0.01).

![Epinephrine administration in anaphylaxis cases. ED, Emergency Department. χ^2^ = 30.767, *p* \< 0.01.](apa-10-e1-g001){#F1}

Most epinephrine doses were given via intramuscular route (87.6%). Other routes used include subcutaneous (5.5%), inhalation via nebulization (4.1%), intravenous bolus (1.4%), and continuous intravenous drip for a patient diagnoses with anaphylactic shock (1.4%). Majority of cases diagnosed as anaphylaxis (47.5%) received epinephrine within less than 10 minutes from time of arrival at ED. Of the patients who were not diagnosed as anaphylaxis, more than half (58.3%) eventually received epinephrine but only after 60 minutes ([Fig. 2](#F2){ref-type="fig"}).

![Time interval from arrival at Emergency Department (ED) to administration of epinephrine. χ^2^ = 2.969, *p* \< 0.05.](apa-10-e1-g002){#F2}

[Table 6](#T6){ref-type="table"} shows the rest of the management plans for the patients, including other medications given aside from epinephrine, referral to an allergist, and the disposition after being discharged from the ED. There was no difference in the referral rates whether the patients were initially diagnosed as anaphylaxis or not. The 14 patients who were admitted at the intensive care unit (13.3%), all presented with hypotension at the ED. All admitted cases were discharged stable, mostly after 1 day of hospital stay. There were no cases of mortality among admitted patients.

###### Management care plan

![](apa-10-e1-i006)

  Variable                                          Diagnosed as Anaphylaxis at ED (n = 70)   Not diagnosed as Anaphylaxis at ED (n = 35)   Total (n = 105)   
  ------------------------------------------------- ----------------------------------------- --------------------------------------------- ----------------- ------------
  Other drugs administered aside from epinephrine                                                                                                             
                                                    Corticosteroid                            66 (94.3)                                     34 (97.1)         100 (95.2)
                                                    Antihistamine                             64 (91.4)                                     34 (97.1)         98 (93.3)
                                                    Bronchodilator                            48 (68.6)                                     18 (51.4)         66 (62.8)
                                                    H~2~ blocker/proton pump inhibitor        27 (38.6)                                     25 (71.4)         52 (49.5)
  Referral to an allergist                                                                                                                                    
                                                    With referral                             32 (45.7)                                     17 (48.6)         49 (46.7)
                                                    Without referral                          38 (54.3)                                     18 (51.4)         56 (53.3)
  Disposition                                                                                                                                                 
                                                    Admitted to regular room                  56 (80)                                       24 (68.6)         80 (76.2)
                                                    Admitted to ICU                           13 (18.6)                                     1 (2.9)           14 (13.3)
                                                    Discharged from ED                        1 (1.4)                                       9 (25.7)          10 (9.5)
                                                    DAMA from ED                              0 (0)                                         1 (2.9)           1 (1)

Values are presented as number (%).

ED, Emergency Department; ICU, intensive care unit; DAMA, discharged against medical advice.

DISCUSSION
==========

There are few data on the incidence of anaphylaxis. Incidence rate calculated in our study was 0.03%, which was comparable to studies done in hospitals in Bangkok, Pakistan and Spain of 0.01%--0.08% \[[@B6][@B8][@B9]\].

Studies on the epidemiology of anaphylaxis were hampered by a lack of consensus on the definition and criteria for its diagnosis. This was until recently when in 2005 the NIAID/FAAN established a consensus on the definition and diagnostic criteria to satisfy epidemiological, research, and clinical needs. Accurate diagnosis was also hindered by the lack of accurate diagnostic coding. Our study used the ICD-10 codes for anaphylaxis and allergy-related disorders to search for the charts that we reviewed. The ICD version used matter because reports show that anaphylaxis incidence varied between studies using the 9th or 10th ICD codes as selection criteria of cases using the NIAID/FAAN criteria \[[@B10]\]. Other studies have likewise shown that the available codes were not very helpful when attempting to describe anaphylaxis \[[@B11][@B12][@B13]\], and there was also an insufficient number of codes available to document episodes of diagnosed anaphylaxis \[[@B14]\].

Immediate recognition and accurate diagnosis of anaphylaxis at the point of care, especially in the setting of an ED, is crucial for initiation of urgent and appropriate care. It was estimated that 57% of anaphylaxis cases in the ED are misdiagnosed \[[@B6]\]. In our study, anaphylaxis was diagnosed by ED physicians in a little more than half (66.7%) of cases, despite fulfilling the criteria of the NIAID/FAAN consensus. Kastner et al. \[[@B15]\] even suggested that there appears to be excessive caution in using the term anaphylaxis by physicians.

Labelling a case as anaphylaxis matters because it was shown in our study that there were significantly more patients given epinephrine versus those diagnosed as "hypersensitivity reaction" or "urticaria." This observation is consistent with other studies showing that patients labelled as anaphylaxis at the ED received epinephrine more often, regardless of the severity of their symptoms than patients diagnosed with other allergy-related diagnoses \[[@B6][@B16]\]. All in all, only about 70% of patients seen in our ED received epinephrine despite fulfilling the criteria of the NIAID/FAAN consensus. Epinephrine was also given in a timelier manner when anaphylaxis was the diagnosis.

These findings are not unique to our study. Several studies have demonstrated inconsistent anaphylaxis management in the ED showing even less frequent epinephrine use \[[@B17][@B18][@B19][@B20][@B21][@B22]\], and significant delay in epinephrine administration \[[@B23][@B24][@B25][@B26][@B27]\].

In our study, other medications were also given more often than epinephrine. Even with the lack of evidence that antihistamines and corticosteroids are life-saving in the acute management of anaphylaxis \[[@B28]\], these were given to more anaphylaxis cases than epinephrine (93% and 95% respectively).

The route of administration of epinephrine is also part of the current recommendation for anaphylaxis management. In some studies, lack of knowledge of the correct route of epinephrine administration was an identified gap, with physicians administering via the subcutaneous or intravenous route rather than the recommended intramuscular route \[[@B20][@B21][@B23][@B29][@B30][@B31]\]. It was encouraging to see that in our study, the majority of ED physicians gave epinephrine intramuscularly.

Evidence has shown that delayed epinephrine injection is associated with higher morbidity and mortality \[[@B32]\]. It was fortunate in our study that despite not receiving epinephrine, or a significant delay in epinephrine administration, there were no mortalities. This might be partly due to that fact that these patients were the ones with milder symptoms. Patients who had a higher risk for mortality and morbidity (respiratory compromise, low oxygen saturation, and hypotension) were appropriately diagnosed as anaphylaxis and given epinephrine in a well-timed manner. Data from our study showed that diagnosis of anaphylaxis at the ED was found to be dependent on the signs and symptoms of wheezing, oxygen saturation of \<95%, abdominal pain, and hypotension. It appears therefore that patients need to present with moderate to severe signs and symptoms for anaphylaxis to be consistently diagnosed. The systematic review done by Kastner et al. \[[@B15]\] noted that some practitioners still think that "shock" needs to be present for anaphylaxis to be diagnosed even though this has been eliminated from new definitions. Therefore, insufficient knowledge by medical practitioners to identify the signs and symptoms of anaphylaxis or to correctly diagnose anaphylaxis is a major gap that needs to be addressed.

As in literature, our study showed that a large percentage of anaphylaxis cases had unknown triggers. Among those cases with identified triggers from history, the most common agents found in this study were food and drugs. Unfortunately, we failed to include specific ICD coding for anaphylaxis secondary to insect sting during the chart review, which could have affected our results showing only 5 cases triggered by insect stings. Among food triggers, crustaceans, fish, and peanut were the most common. NSAIDs were the most frequent among drugs. All these agents are also indicated by WAO to be significant triggers of anaphylaxis globally \[[@B10]\]. Recent studies have demonstrated that food-induced anaphylaxis have shown increasing trend not just in pediatric patients but also in all age groups \[[@B33][@B34]\]. However, we need to consider possible overestimation of food allergy as a trigger. Currently, the majority of available data based on self-reporting generally overestimates food allergy prevalence by a factor of 3 to 4 \[[@B35][@B36][@B37]\]. The study done by Alvarez-Perea et al. \[[@B6]\] confirmed that after an allergy workup, the trigger differed in many cases from that reported by the patient or that proposed by the physician in the ED. And in those patients who did not know the cause of their reaction, the work up revealed the real trigger. The possible disconnect between the suspected culprit and real cause of the anaphylaxis, therefore, highlights the need for improved follow-up care for the patients after the acute event.

Anaphylaxis management guidelines recommend that patients who had previous anaphylaxis episode be prescribed with epinephrine and referred to an allergist for the long-term management and prevention of anaphylaxis \[[@B38]\]. In our study, less than half of anaphylaxis cases were referred to an allergist. Only 1 patient was given a prescription of epinephrine upon discharge from the ED. Because the onset of anaphylaxis symptoms often occurs in the community setting \[[@B39]\], at-risk patients should have epinephrine auto-injectors to provide rapid intramuscular administration of epinephrine \[[@B40][@B41][@B42]\]. There are numerous evidences demonstrating that delayed medication administration leads to increased risk of progression to severe anaphylaxis \[[@B27][@B28][@B43][@B44]\]. The dearth of prescription of epinephrine in our study can be due to the fact that self-injectable epinephrine is actually not available in the Philippines. This lack of access to self-injectable epinephrine for patients in the Philippines is a crucial point as this is a cornerstone for long-term management of anaphylaxis. Some allergists, therefore, instruct caregivers and patients to draw up the dose from a 1-mL ampule. Others have tried to use unsealed syringes prefilled by the physician with the appropriate epinephrine dose. Studies have shown however that dose preparation by a lay person from an ampule can be delayed as much as 3--4 minutes and can be inaccurate \[[@B45]\], and epinephrine in a prefilled syringe typically degrades within a few months from air exposure \[[@B46]\]. Clearly, these make-shift solutions are nowhere near adequate.

The limitations of our study are inherent in all studies that use a retrospective method, with only medical records as the sole source for data. Chart reviews could be lacking in vital information regarding the clinical assessments during the ED visit including exposure to allergens, progression of the symptoms, or other parts of the history that could help differentiate from other diseases including laryngeal or bowel angioedema with concomitant urticarial for instance. There was no way for us to verify the accuracy of the data in the medical records, or interact with the patients to probe more on their history.

The incidence of anaphylaxis in this study is 0.03%, comparable to studies in other centers. Despite available clinical practice guidelines, diagnosis and management of anaphylaxis continue to be inconsistent. Our study shows that there appears to be a lack of clarity among ED physicians on how to diagnose anaphylaxis consistently. The labelling of anaphylaxis is critical as these patients were more likely to receive epinephrine in a timely manner than those who were given other allergy-related diagnoses. The lack of recognition of anaphylaxis meant that patients often do not receive first-line epinephrine treatment. Although epinephrine was given more often to anaphylaxis cases by ED physicians in our institution as compared to previous studies, the situation still leaves a lot to be desired. Especially considering that epinephrine administration is the single most important determinant of outcomes of anaphylaxis. The role of the ED physician cannot be overly emphasized in the management of anaphylaxis. Discharge from the ED represents the transition from acute stabilization of the patient to transition to long-term management. They play a pivotal role in correctly identifying anaphylaxis, and then initiate long-term management during discharge including referral to an allergist and the provision of epinephrine in an out-patient setting. Further education and quality improvement programs, and then prospective methods to assess quality of diagnosis and management of anaphylaxis in the ED are imperative.
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